Patents Examined by Amanda L Aguirre
  • Patent number: 11186720
    Abstract: A new yellow pigment excellent in both brightness and coloring power is provided. It has been found that dimerization of a specific quinophthalone skeleton gives more selective absorption and transmittance. Furthermore, the dimerization method was also studied, and it has been found that excessive reddish tone can be suppressed by cleaving the conjugate using a methylene chain as a spacer instead of simply employing a direct bond. In addition, dispersibility has been improved by polyhalogenation and introduction of an imide structure. Furthermore, a coloring agent containing the quinophthalone compound and a coloring composition containing the coloring agent are provided.
    Type: Grant
    Filed: June 13, 2019
    Date of Patent: November 30, 2021
    Assignee: DIC CORPORATION
    Inventors: Hitoshi Kondo, Tatsuya Shigehiro, Kengo Yasui
  • Patent number: 11186719
    Abstract: The present disclosure embodies compounds of Formula I, methods of use thereof, and kits thereof: that are useful in connection with the detection of analytes of all types (e.g., biological molecules such as proteins, organic molecules, natural or synthetic molecules). The disclosure is particularly applicable to detection of proteins and nucleic acids using all types of membrane-based assays by techniques such as Western blotting, Dot blotting, Southern blotting, and Northern blotting.
    Type: Grant
    Filed: May 7, 2019
    Date of Patent: November 30, 2021
    Assignee: LI-COR, INC.
    Inventors: Silvano Sanchini, Rose Skopp, Vassil Elitzin, Nisha Padhye, Teresa Urlacher
  • Patent number: 11179368
    Abstract: The present invention concerns substituted indoline derivatives, methods to prevent or treat dengue viral infections by using said compounds and also relates to said compounds for use as a medicine, more preferably for use as a medicine to treat or prevent dengue viral infections. The present invention furthermore relates to pharmaceutical compositions or combination preparations of the compounds, to the compositions or preparations for use as a medicine, more preferably for the prevention or treatment of dengue viral infections. The invention also relates to processes for preparation of the compounds.
    Type: Grant
    Filed: March 29, 2018
    Date of Patent: November 23, 2021
    Assignees: JANSSEN PHARMACEUTICALS, INC., KATHOLIEKE UNIVERSITEIT LEUVEN
    Inventors: Dorothée Alice Marie-Eve Bardiot, Bart Rudolf Romanie Kesteleyn, Jean-François Bonfanti, Pierre Jean-Marie Bernard Raboisson, Arnaud Didier M Marchand
  • Patent number: 11180444
    Abstract: The compounds with the general formula I are disclosed where n1 is the number of carbon atoms connected to nitrogen atom by a double bond and can take on values of 25 to 41, and where n2 is the number of —CH2— groups and can take on values of 15 to 23, as well as their biologically acceptable salts and solvates.
    Type: Grant
    Filed: February 21, 2017
    Date of Patent: November 23, 2021
    Assignee: NOVUM SPERO LTD
    Inventor: Besim Hulaj
  • Patent number: 11180451
    Abstract: The present disclosure provides conjugate structures and hydrazinyl-pyrrolo compound structures used to produce these conjugates. The disclosure also encompasses methods of production of such conjugates, as well as methods of using the same.
    Type: Grant
    Filed: December 20, 2019
    Date of Patent: November 23, 2021
    Assignee: Redwood Bioscience, Inc.
    Inventors: David Rabuka, Aaron Edward Albers, Romas Alvydas Kudirka, Albert W. Garofalo
  • Patent number: 11174254
    Abstract: The present invention relates to a 1,2-dihydropyrrol[3,4-c]pyridin/pyrimidin-3-one derivative substituted by N-(3-aminophenyl)acrylamide and a preparation method and pharmaceutical use thereof. In particular, the present invention relates to a compound of formula (II) or a pharmaceutically acceptable salt, stereoisomer, solvate, or prodrug thereof and a preparation method and application of the same. The definition of each substituent in the formula is described in detail in the specification and claims.
    Type: Grant
    Filed: August 3, 2018
    Date of Patent: November 16, 2021
    Assignees: YANGTZE RIVER PHARMACEUTICAL GROUP CO., LTD., SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD.
    Inventors: Shuchun Guo, Fusheng Zhou, Xiang Chen, Jinzhu Zhao, Dong Huang, Jing Xie, Changjiang Qiao, Wan He, Kai Zhang, Xi Chen, Jiong Lan
  • Patent number: 11166924
    Abstract: This invention relates to therapeutic compounds and compositions, and methods for their use in the prevention or treatment of neurological disorders. In particular, the invention relates to N-methyl-D-aspartate receptor (NMDAR) allosteric modulators and methods for their use in the prevention or treatment of disorders or conditions caused by or related to NMDAR dysfunctions. The invention also relates to a method for identifying NMDAR allosteric modulators.
    Type: Grant
    Filed: September 26, 2017
    Date of Patent: November 9, 2021
    Assignee: Qingdao Primedicine Pharmaceutical Company, Ltd.
    Inventors: Yu Tian Wang, Peter Axerio-Cilies
  • Patent number: 11161801
    Abstract: The present invention provides cationic pillar[n]arenes, e.g., positively charged poly-ammonium, poly-phosphonium and poly-imidazolium pillar[5-6]arene derivatives, capable of inhibiting or preventing biofilm formation, and facilitating existing biofilm decomposition; as well as compositions thereof and methods of use.
    Type: Grant
    Filed: August 3, 2016
    Date of Patent: November 2, 2021
    Assignee: Ramot At Tel-Aviv University Ltd.
    Inventors: Yoram Cohen, Micha Fridman, Roymon Joseph, Alissa Naugolny, Mark Feldman, Ido M. Herzog, Dana Kaizerman
  • Patent number: 11161812
    Abstract: Disclosed are novel processes for the production of cyclic imide compounds such as N-hydroxyphthalimide (NHPI). The processes may be particularly well-suited for commercial-scale production of cyclic imides such as NHPI. Such cyclic imide compounds are suitable for use as oxidation catalysts, and specifically may be used to oxidize cyclohexylbenzene to cyclohexyl-1-phenyl-1-hydroperoxide. Such an oxidation may be particularly useful in a process for the production of phenol and/or cyclohexanone from benzene via a process comprising hydroalkylation of benzene to cyclohexylbenzene, oxidation of the cyclohexylbenzene to cyclohexyl-1-phenyl-1-hydroperoxide, and cleavage of the cyclohexyl-1-phenyl-1-hydroperoxide to phenol and cyclohexanone. The cyclic imide production process may advantageously include water washing and reactant recovery steps to maximize purity and yield.
    Type: Grant
    Filed: April 18, 2017
    Date of Patent: November 2, 2021
    Assignee: ExxonMobil Chemical Patents Inc.
    Inventors: Jörg F. W. Weber, Helge Jaensch, Andrew R. Witt, Christopher L. Becker, Kirk C. Nadler, Kendele S. Galvan, Amy B. Batton
  • Patent number: 11155521
    Abstract: A compound, or a pharmaceutically acceptable salt or ester thereof, comprising (i) a CB1 receptor mediating scaffold and (ii) a second therapeutic scaffold.
    Type: Grant
    Filed: March 4, 2016
    Date of Patent: October 26, 2021
    Assignee: The United States of America as represented by the Secretary, Department of Health and Human Services
    Inventors: Resat Cinar, George Kunos, Malliga R. Iyer, William A. Gahl, Bernadette R. Gochuico, May Christine Vergara Malicdan
  • Patent number: 11155526
    Abstract: Provided is a production method of kakeromycin and a derivative thereof showing an antifungal activity and cytotoxicity and expected as a new antifungal agent or anticancer agent, by chemical synthesis. A production method of a compound represented by the formula (1): wherein R is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group; and n is 0 or 1, or a salt thereof, including a step of subjecting a compound represented by the formula (2): wherein R and n are as defined above, or a salt thereof, to an oxidation reaction.
    Type: Grant
    Filed: September 21, 2018
    Date of Patent: October 26, 2021
    Assignees: OP BIO FACTORY CO., LTD., SEED RESEARCH INSTITUTE CO., LTD.
    Inventors: Teruhiko Ishikawa, Morita Iwami
  • Patent number: 11158818
    Abstract: The present specification provides the compound represented by Formula 1 and an organic solar cell including the same.
    Type: Grant
    Filed: March 16, 2018
    Date of Patent: October 26, 2021
    Inventors: Bogyu Lim, Songrim Jang, Doowhan Choi, Ji Hoon Kim
  • Patent number: 11154060
    Abstract: Compounds of Formula (IA) or Formula (IB): (IA/IB) wherein the substituents are as defined in claim 1, useful as pesticides, especially as fungicides.
    Type: Grant
    Filed: May 19, 2017
    Date of Patent: October 26, 2021
    Assignee: SYNGENTA PARTICIPATIONS AG
    Inventors: Thomas James Hoffman, Daniel Stierli, Farhan Bou Hamdan
  • Patent number: 11154548
    Abstract: The invention discloses a monosubstituted or polysubstituted amphiphilic hypocrellin derivative, and a preparation method and application thereof. The amphiphilic hypocrellin derivative substituted by a group containing PEG, a quaternary ammonium salt or the like prepared according to the invention has an obvious red shift in its absorption spectrum and a significantly enhanced molar extinction coefficient, compared with the parent hypocrellin, can efficiently produce singlet state oxygen and other reactive oxygen species under photosensitive conditions; has different amphiphilicities and increased biocompatibility with cells or tissues by regulating its hydrophilicity and hydrophobicity; can meet the requirements of different clinical drugs, and solves the requirements of different drug delivery methods for different drug hydrophilicity and lipophilicity.
    Type: Grant
    Filed: October 21, 2016
    Date of Patent: October 26, 2021
    Assignee: TECHNICAL INSTITUTE OF PHYSICS AND CHEMISTRY OF THE CHINESE ACADEMY OF SCIENCES
    Inventors: Pengfei Wang, Jiasheng Wu, Weimin Liu, Ying Gu, Jiechao Ge, Xiuli Zheng, Hongyan Zhang
  • Patent number: 11148999
    Abstract: The present invention provides, in part a novel class of nonoate compounds which exhibit nitric oxide releasing activity and their pharmaceutically acceptable salts, esters and prodrugs. The compounds release nitric oxide upon activation by contact with plasma. The present invention also relates to the use of the disclosed compounds to deliver nitric oxide to treat disorders arising from nitric oxide dysregulation.
    Type: Grant
    Filed: June 21, 2017
    Date of Patent: October 19, 2021
    Assignee: MedChem Partners, LLC
    Inventors: Steven Riesinger, Tsvetelina Lazarova, Zinadia Ribkovskaia
  • Patent number: 11149012
    Abstract: 5-HMF derivative compounds that bind covalently with hemoglobin are provided. Methods of treating sickle cell disease and other hypoxia-related disorders by administering such compounds are also provided.
    Type: Grant
    Filed: October 7, 2020
    Date of Patent: October 19, 2021
    Assignees: King Abdulaziz University, Virginia Commonwealth University
    Inventors: Abdelsattar Mansour Ebeid Omar, Moustafa El-Sayed El-Araby, Martin K. Safo
  • Patent number: 11142523
    Abstract: The present invention relates to 1,3-thiazol-2-yl substituted benzamide compounds of general formula (I) as described and defined herein, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neurogenic disorder, as a sole agent or in combination with other active ingredients.
    Type: Grant
    Filed: October 1, 2019
    Date of Patent: October 12, 2021
    Assignee: Bayer Aktiengesellschaft
    Inventors: Adam James Davenport, Nico Bräuer, Oliver Martin Fischer, Andrea Rotgeri, Antje Rottmann, Ioana Neagoe, Jens Nagel, Anne-Marie Godinho-Coelho, Jürgen Klar
  • Patent number: 11142505
    Abstract: Selected compounds, compositions, and methods for inhibiting BACE are presented that have relatively high selectivity towards APP via interaction of the inhibitor with both BACE and APP.
    Type: Grant
    Filed: August 29, 2016
    Date of Patent: October 12, 2021
    Assignee: The Regents of the University of California
    Inventors: Varghese John, Patricia Spilman, Barbara Jagodzinska
  • Patent number: 11133479
    Abstract: The present specification relates to an organic solar cell including a first electrode; a second electrode; and one or more organic material layers including a photoactive layer, wherein the photoactive layer includes an electron donor and an electron acceptor, the electron donor includes a polymer including a first unit represented by Chemical Formula 1; a second unit represented by Chemical Formula 2; and a third unit represented by Chemical Formula 3, and the electron acceptor includes a non-fullerene-based compound.
    Type: Grant
    Filed: June 18, 2018
    Date of Patent: September 28, 2021
    Assignee: LG Chem, Ltd.
    Inventors: Doowhan Choi, Jiyoung Lee, Bogyu Lim, Songrim Jang, Ji Hoon Kim
  • Patent number: 11130744
    Abstract: Disclosed are compounds, for example, compounds of formula I, wherein R, R0, R1-R8, n, X, Y, Y?, and E are as described herein, pharmaceutical compositions containing such compounds, and methods of treating or preventing a disease or condition, for example, cancer.
    Type: Grant
    Filed: March 30, 2020
    Date of Patent: September 28, 2021
    Assignee: ADT Pharmaceuticals, LLC
    Inventors: Gary A. Piazza, Xi Chen, Adam B. Keeton, Michael R. Boyd